Bristol-Myers Squibb (BMY *) Aktienübersicht Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen BMY * Community Fair Values See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bristol-Myers Squibb Company Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Bristol-Myers Squibb Historische Aktienkurse Aktueller Aktienkurs US$885.00 52-Wochen-Hoch US$1,261.00 52-Wochen-Tief US$713.00 Beta 0.39 1 Monat Veränderung 1.14% 3 Monate Veränderung -27.14% 1 Jahr Veränderung 15.34% 3 Jahre Veränderung -42.79% 5 Jahre Veränderung -34.02% Veränderung seit IPO 280.48%
Aktuelle Nachrichten und Updates Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels Jun 27
First quarter dividend of US$0.62 announced Jun 23 Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025 Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis Jun 11 Weitere Updates anzeigen Bristol-Myers Squibb Company(NYSE:BMY) dropped from Russell 1000 Defensive Index
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of RemS Programs Within Bristol Myers Squibb's Cell Therapy Labels Jun 27
First quarter dividend of US$0.62 announced Jun 23 Bristol-Myers Squibb Company Announces Quarterly Dividend, Payable on August 1, 2025 Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA -1 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis Jun 11
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo®? (nivolumab) Across Multiple Solid Tumor Indications May 28
Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline May 23
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo®? (Nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with Pd-1 Expression 1% May 16
Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT). May 14
Bristol Myers Squibb Announces Executive Changes May 06
Executive VP recently bought Mex$4.0m worth of stock May 01
First quarter 2025 earnings released: EPS: US$1.21 (vs US$5.89 loss in 1Q 2024) Apr 26
Bristol-Myers Squibb Company Revises Earnings Guidance for the Year 2025 Apr 24
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia Apr 23
Bristol Myers Squibb Announces U.S. Food and Drug Administration Updates CAMZYOS®? (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications Apr 18
New minor risk - Share price stability Apr 16
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial Apr 16
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Opdivo (nivolumab) Plus Yervoy (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma Apr 12
U.S. Food and Drug Administration Approves Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer Apr 09 Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Us Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights Mar 28
Upcoming dividend of US$0.62 per share Mar 28
Bristol-Myers Squibb Company, Annual General Meeting, May 06, 2025 Mar 28
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Mar 14
Bristol-Myers Squibb Company to Report Q1, 2025 Results on Apr 24, 2025 Mar 13
Bristol-Myers Squibb Company (NYSE:BMY) agreed to acquire 2seventy bio, Inc. (NasdaqGS:TSVT) for approximately $280 million. Mar 12
Fourth quarter dividend of US$0.62 announced Mar 10
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis Mar 09
Bristol Myers Squibb Receives European Commission Approval for Opdivo®? (Nivolumab) Plus Yervoy®? (Ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma Mar 07
Bristol-Myers Squibb Company Announces Quarterly Dividend on Common Stock, Payable on May 1, 2025 Mar 04 Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Executive VP recently bought Mex$2.0m worth of stock Feb 20
Bristol-Myers Squibb Company Provides Update on Phase 3 Relativity-098 Trial Feb 14
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (Lisocabtagene Maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma Feb 10
Full year 2024 earnings released: US$4.41 loss per share (vs US$3.88 profit in FY 2023) Feb 07 Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap Jan 27
Bristol Myers Squibb Announces FDA Approval of Cobenfy Jan 08
Upcoming dividend of US$0.62 per share Dec 30
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications Dec 28 Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025 Dec 19
Third quarter dividend of US$0.62 announced Dec 16
Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025 Dec 12
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline Dec 10
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms Nov 20
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors Nov 16
Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024 Nov 12
Executive VP recently bought Mex$2.0m worth of stock Nov 06
Third quarter 2024 earnings released: EPS: US$0.60 (vs US$0.94 in 3Q 2023) Nov 01 Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024 Oct 28
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) Oct 04
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting Sep 29
Upcoming dividend of US$0.60 per share Sep 27
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Sep 27
Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis Sep 18
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma Sep 16
Second quarter dividend of US$0.60 announced Sep 13
Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024 Sep 12
New major risk - Share price stability Sep 10
Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Sep 02
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma Aug 21
European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Aug 19
Second quarter 2024 earnings released: EPS: US$0.83 (vs US$0.99 in 2Q 2023) Jul 28
Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024 Jul 26
New minor risk - Share price stability Jul 24
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma Jul 20
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Jun 22 Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024
First quarter dividend of US$0.60 announced Jun 20
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024 Jun 19
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024 Jun 18
Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial Jun 06 Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Jun 01
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine May 30
Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis May 18
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma May 17
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial May 11
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) May 08
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer May 07
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma Apr 27
First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023) Apr 25
Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Apr 10
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Apr 06
European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept) Apr 03
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease Mar 29 Aktionärsrenditen BMY * MX Pharmaceuticals MX Markt 7D -2.9% -1.8% 2.3% 1Y 15.3% 1.2% 3.8%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: BMY * übertraf die Branche MX Pharmaceuticals , die im vergangenen Jahr eine Rendite von 1.2 erzielte.
Rendite vs. Markt: BMY * übertraf den Markt MX, der im vergangenen Jahr eine Rendite von 3.8 erzielte.
Preisvolatilität Is BMY *'s price volatile compared to industry and market? BMY * volatility BMY * Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.5% 10% most volatile stocks in MX Market 7.1% 10% least volatile stocks in MX Market 2.7%
Stabiler Aktienkurs: Es sind keine Daten verfügbar.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von BMY * im vergangenen Jahr zu bestimmen.
Über das Unternehmen Gegründet Mitarbeiter CEO Website 1887 34,100 Chris Boerner www.bms.com
Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Produkte für die Bereiche Onkologie, Hämatologie, Immunologie, Herz-Kreislauf, Neurowissenschaften und andere Bereiche an. Zu den Produkten des Unternehmens gehören Eliquis zur Verringerung des Risikos eines Schlaganfalls/einer systemischen Embolie bei nicht-valvulärem Vorhofflimmern und zur Behandlung von TVT/PE; Opdivo für verschiedene Krebsindikationen; Pomalyst/Imnovid für das multiple Myelom; Orencia für aktive rheumatoide Arthritis und Psoriasis-Arthritis; und Sprycel zur Behandlung von Patienten mit Philadelphia-Chromosom-positiver chronischer myeloischer Leukämie.
Mehr anzeigen Bristol-Myers Squibb Company's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Bristol-Myers Squibb im Vergleich zum Marktanteil des Unternehmens? BMY * grundlegende Statistiken Marktanteil Mex$1.78t Gewinn(TTM ) Mex$102.15b Umsatz(TTM ) Mex$897.97b
17.4x
Kurs-Gewinn-Verhältnis 2.0x
Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) BMY * Gewinn- und Verlustrechnung (TTM ) Einnahmen US$47.64b Kosten der Einnahmen US$12.06b Bruttogewinn US$35.58b Sonstige Ausgaben US$30.16b Umsatz US$5.42b
Zuletzt gemeldete Gewinne
Mar 31, 2025
Datum des nächsten Gewinnberichts
Jul 31, 2025
Gewinn per Aktie (EPS) 2.66 Bruttomarge 74.69% Nettogewinnspanne 11.38% Schulden/Eigenkapital-Verhältnis 285.1%
Wie hat sich BMY * auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden 5.4%
Aktuelle Dividendenrendite Bis wann müssen Sie BMY * kaufen, um eine kommende Dividende zu erhalten? Bristol-Myers Squibb Dividendentermine Ex-Dividenden Datum Jul 03 2025 Datum der Dividendenzahlung Aug 01 2025 Tage bis Ex-Dividende 2 days Tage bis zum Datum der Dividendenzahlung 31 days
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/06/30 19:43 Aktienkurs zum Tagesende 2025/06/27 00:00 Gewinne 2025/03/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Bristol-Myers Squibb Company wird von 47 Analysten beobachtet. 26 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung David Toung Argus Research Company Ishan Majumdar Baptista Research Charles Butler Barclays
44 weitere Analysten anzeigen